Carlee Moser Selected Research

romlusevimab

5/2024	Characterization of treatment resistance and viral kinetics in the setting of single- versus dual-active monoclonal antibodies against SARS-CoV-2.
1/2023	Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carlee Moser Research Topics

Disease

22	COVID-19 05/2024 - 09/2021
7	Inflammation (Inflammations) 01/2023 - 08/2015
6	Acquired Immunodeficiency Syndrome (AIDS) 01/2023 - 09/2016
5	Insulin Resistance 01/2022 - 09/2016
3	Infections 10/2023 - 10/2021
2	Myocardial Infarction 10/2020 - 01/2019
2	HIV Infections (HIV Infection) 01/2017 - 01/2016
1	Disease Progression 05/2024
1	Viremia 01/2023
1	Glucose Intolerance 01/2022
1	Weight Gain 01/2022
1	Body Weight (Weight, Body) 12/2021
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021
1	Stroke (Strokes) 01/2019
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2017
1	Atherosclerosis 01/2017
1	Parkinson Disease (Parkinson's Disease) 01/2012

Drug/Important Bio-Agent (IBA)

10	Monoclonal AntibodiesIBA 05/2024 - 12/2021
8	Antiviral Agents (Antivirals)IBA 05/2024 - 08/2015
7	bamlanivimabIBA 11/2023 - 09/2021
7	RNA (Ribonucleic Acid)IBA 10/2023 - 01/2021
5	Biomarkers (Surrogate Marker)IBA 01/2023 - 08/2015
4	C-Reactive ProteinIBA 01/2022 - 08/2015
3	ruxolitinibIBA 01/2023 - 12/2021
3	AdiponectinIBA 01/2022 - 01/2021
3	Raltegravir Potassium FDA Link 01/2022 - 08/2015
3	LeptinIBA 01/2022 - 01/2021
3	Interleukin-6 (Interleukin 6)IBA 12/2021 - 08/2015
2	romlusevimabIBA 05/2024 - 01/2023
2	amubarvimabIBA 05/2024 - 01/2023
2	Viral RNAIBA 10/2023 - 08/2022
2	nirmatrelvir and ritonavir drug combinationIBA 01/2023 - 08/2022
2	Immunoglobulin G (IgG)IBA 01/2023 - 12/2022
2	Atazanavir Sulfate (Reyataz)FDA Link 01/2022 - 08/2015
2	Darunavir (Prezista)FDA Link 01/2022 - 08/2015
2	Ritonavir (Norvir)FDA Link 01/2022 - 08/2015
2	LipidsIBA 01/2022 - 01/2021
2	Tenofovir (Viread)FDA Link 01/2022 - 09/2016
2	Emtricitabine (Emtriva)FDA Link 01/2022 - 09/2016
2	Lipopolysaccharide ReceptorsIBA 12/2021 - 08/2015
2	HDL LipoproteinsIBA 01/2021 - 01/2017
2	Protease Inhibitors (Protease Inhibitor)IBA 09/2016 - 08/2015
1	EpitopesIBA 11/2023
1	Messenger RNA (mRNA)IBA 11/2023
1	Therapeutic UsesIBA 11/2023
1	Neutralizing AntibodiesIBA 10/2023
1	camostatIBA 10/2023
1	VaccinesIBA 01/2023
1	Sirolimus (Rapamycin)FDA Link 01/2023
1	Immunoglobulins (Immunoglobulin)IBA 01/2023
1	SAB-185IBA 01/2023
1	tixagevimabIBA 01/2023
1	cilgavimabIBA 01/2023
1	Janus Kinase InhibitorsIBA 01/2022
1	AdipokinesIBA 01/2022
1	AntigensIBA 12/2021
1	Nucleic AcidsIBA 12/2021
1	CytokinesIBA 12/2021
1	Cytochrome P-450 CYP3AIBA 12/2021
1	efavirenz (Sustiva)FDA Link 12/2021
1	Janus Kinase 1IBA 12/2021
1	Advanced Glycation End ProductsIBA 10/2021
1	HDL CholesterolIBA 01/2021
1	Triglycerides (Triacylglycerol)IBA 01/2021
1	Nitric Oxide Synthase (NO Synthase)IBA 01/2021
1	N,N-dimethylarginine (asymmetric dimethylarginine)IBA 01/2021
1	lipopolysaccharide-binding proteinIBA 10/2020
1	DNA (Deoxyribonucleic Acid)IBA 01/2020
1	Lipoproteins (Lipoprotein)IBA 01/2017
1	Glucose (Dextrose)FDA LinkGeneric 09/2016
1	fibrin fragment D (D-dimer)IBA 08/2015
1	Integrase InhibitorsIBA 08/2015
1	SynucleinsIBA 01/2012

Therapy/Procedure

13	Therapeutics 11/2023 - 08/2015
5	Art Therapy 01/2019 - 08/2015
1	Investigational Therapies (Experimental Therapy) 11/2022